EL7.AI
StocksMedium•23 October 2026•
3 min read

Lycia Therapeutics Reports Preliminary 96% Reduction in IgE Among Treatment Recipients

Key Facts

1The mean maximum preliminary reduction in IgE among participants who received LCA-0061 was about 96%.
2The preliminary plan included an offering of 14.7 million shares at a price range of $16 to $18 a share.
3The company reported revenue of $4.44 million and a net loss of $30.03 million for the twelve months ended June 30, 2026.
4The company expected data on LCA-0061 and LCA-0321 in 2027, with preliminary data on LCA-0062 potentially available in the second half of 2027.

Lycia Therapeutics shares began trading on October 23, 2026, according to the start date in a correction to the earlier report. The company had set the price of its initial public offering at $18 a share, according to the earlier report published by EL7 on October 22. No documented opening or closing prices for the first day are available in the information provided, so the stock’s direction or the size of any move cannot be determined. In its preliminary registration statement, the company planned to offer 14.7 million shares at a price range of $16 to $18 a share. The set price was at the top of that range, according to the information in the earlier report.

Lycia plans to use the net proceeds from the offering, along with its available cash, to advance its clinical programs in its IgE portfolio and its Graves’ disease program. The IgE program includes candidates LCA-0061 and LCA-0062, while LCA-0321 targets Graves’ disease, according to the company’s filing with the U.S. Securities and Exchange Commission. The company also allocated funds to research and development, working capital and general purposes. This puts the offering proceeds at the center of funding for clinical and research work, while the programs remain in early development. The company said in the filing that it wants to “advance the clinical development of its IgE portfolio, including LCA-0061 and LCA-0062, and develop its Graves’ disease program, LCA-0321.”

Lycia focuses on therapies targeting extracellular proteins associated with disease, according to a BioPharma Dive report published on October 22, 2026. LCA-0061, its allergy-related candidate, and LCA-0321, its Graves’ disease candidate, are in Phase 1 testing. The offering prospectus reported preliminary results from the first cohort in the LCA-0061 study, in which the company said the mean maximum reduction in IgE from baseline was 96% among participants who received the treatment. The filing described the results as preliminary, making them an early reading in the clinical development process. The company is still awaiting program data to assess progress in later stages.

The company expected data on LCA-0061 and LCA-0321 in 2027, according to the BioPharma Dive report. LCA-0062, another candidate targeting allergies, could begin testing soon, with preliminary data potentially available in the second half of 2027. These timelines follow the offering, while next steps depend on the progress of clinical studies. The filing also showed revenue of $4.44 million and a net loss of $30.03 million for the twelve months ended June 30, 2026. These figures provide financial context for an offering by a company still focused on developing its therapeutic candidates.